Corbus Pharmaceuticals

CRBPPhase 3

Norwood, United StatesFounded 2009corbuspharma.com

Founded in 2009, Corbus Pharmaceuticals is a publicly-traded company focused on advancing targeted treatments for oncology and metabolic diseases. Its strategy leverages deep biological insight into mechanisms like Nectin-4 in cancer and peripheral CB1 receptors in obesity. The company has progressed its lead oncology asset, CRB-701, into dose optimization studies and recently reported positive Phase 1a safety data for its obesity candidate, CRB-913, positioning it for continued clinical development.

Market Cap

$151.0M

Founded

2009

Focus

Small Molecules

CRBP · Stock Price

USD 8.607.78 (-47.50%)

Historical price data

AI Company Overview

Technology Platform

Program-specific optimization of therapeutic modalities: next-generation antibody-drug conjugate (ADC) engineering with site-specific conjugation for oncology, and peripherally-restricted drug design for metabolic disease.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Lenabasum 5 mg + Lenabasum 20 mg	Diffuse Cutaneous Systemic Sclerosis	Phase 3
Lenabasum 20 mg + Lenabasum 5 mg + Placebo	Dermatomyositis	Phase 3
JBT-101 + Placebo	Dermatomyositis	Phase 2
Lenabasum 20 mg + Lenabasum 5 mg	Cystic Fibrosis	Phase 2
JBT-101 (lenabasum)	Cystic Fibrosis	Phase 2

Funding History

Total raised: $260M

PIPE$100MUndisclosedJul 15, 2020

IPO$75MUndisclosedApr 28, 2016

Series B$60MUndisclosedJun 15, 2015

Series A$25MUndisclosedJan 15, 2014

Opportunities

Corbus has significant opportunities in two massive markets: oncology and obesity.

Success with CRB-701 could capture share in the validated Nectin-4 space by offering a potentially safer and broader-spectrum therapy.

In obesity, CRB-913's novel oral mechanism could address a need for alternatives or complements to injectable GLP-1 agonists, tapping into a rapidly expanding global market.

Risk Factors

Key risks include clinical trial failure for its lead assets, intense competition from established and novel therapies, regulatory hurdles, and dependence on raising capital as a pre-revenue company.

The success of CRB-913 is particularly contingent on demonstrating efficacy that can compete in a market now defined by highly effective GLP-1-based drugs.

Competitive Landscape

Corbus faces formidable competition. In oncology, CRB-701 directly challenges Astellas/Seagen's Padcev, requiring clear demonstration of superior safety or efficacy. In obesity, CRB-913 enters a market dominated by Novo Nordisk and Eli Lilly's potent GLP-1 agonists. Its differentiation lies in its oral administration and unique peripheral CB1 mechanism, but it must prove compelling weight loss benefits and a favorable tolerability profile to gain traction.